Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708890 | 1.00 | NR1H2 (0.53) | NR1H2POLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30708828 | 0.80 | KCNQ3 (0.39) | NR1H2POLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21713012 | 0.80 | NR1H2 (0.50) | NR1H2POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL26969834 | 0.80 | KCNQ3 (0.39) | NR1H2POLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL20541008 | 0.80 | NR1H2 (0.45) | NR1H2POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL21736663 | 0.78 | NR1H2 (0.44) | NR1H2POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29732670 | 0.77 | POLB (0.55) | POLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18005507 | 0.77 | POLB (0.54) | POLBSMN1; SMN2MAPTALDH1A1HSD17B10 | |
| SCHEMBL30708794 | 0.76 | NR1H2 (0.41) | NR1H2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL30708836 | 0.76 | NR1H2 (0.37) | NR1H2POLBSMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | NR1H2 1305/4885POLB 4522/4885SMN1; SMN2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.